Cervix Cancer
112
24
34
49
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.0%
9 terminated out of 112 trials
84.5%
-2.0% vs benchmark
6%
7 trials in Phase 3/4
14%
7 of 49 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 49 completed trials
Clinical Trials (112)
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer
Cervix Hypoxia FAZA
Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV
Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya
AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina
Predictive Clinical and Biological Parameters in Gynecological Cancer
Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
GYNecologic Cancer-Related COGnitive Impairment
Study of a Predictor for Cervix Cancer
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Intra-Pelvic Organ Motion for Cervix Cancer Patient Using Imaging
Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT/Brachytherapy Study
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer
Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.
Hyaluronic Acid-based Gel Spacers in Gynecologic Malignancies
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.